Pfizer's ponsegromab, a monoclonal antibody aimed at blocking GDF-15, showed promise in a mid-stage study by helping cancer patients regain lost weight.
Cancer cachexia is a debilitating syndrome affecting 80% of advanced cancer patients, leading to muscle and fat loss that can hinder treatment effectiveness.
In the Phase 2 study, patients taking the highest dose of ponsegromab regained about 5.6% of their body weight over 12 weeks, along with improved appetite.
With no approved drugs targeting cachexia, Pfizer's potential treatment via ponsegromab could provide critical support for cancer patients experiencing severe weight loss.
Collection
[
|
...
]